Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Therapy-Related Acute Myeloid Leukemia: early-phase trial registry
A small indexed set (11 trials) with no open enrollment listed right now.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · none currently recruiting · #1,577 of 28,707 conditions by registered trial count
Therapy-Related Acute Myeloid Leukemia: 11 US clinical trials tracked, none currently recruiting.
Therapy-Related Acute Myeloid Leukemia is the subject of 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition therapy-related-acute-myeloid-leukemia
OPEN 0 | RECR 0% | LATE 0 | EARLY 11 | RANK #1577 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Therapy-Related Acute Myeloid Leukemia has no open enrollment in this registry pull (11 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Therapy-Related Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Therapy-Related Acute Myeloid Leukemia is recruiting below its size-band peers.
0 of 11 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Therapy-Related Acute Myeloid Leukemia research.
M.D. Anderson Cancer Center accounts for 4 of 11 trials (36.4%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Therapy-Related Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 11 trials that report a genuine target (sentinel values excluded). 8 of those (72.7%) plan for fewer than 100 participants.
-
Therapy-Related Acute Myeloid Leukemia research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
NCT04128501
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
University of Southern California
NCT03330821
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
M.D. Anderson Cancer Center
NCT04062266
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
NCT03009240
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Roswell Park Cancer Institute
NCT04269213
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01420926
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02397720
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01238211
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT01904136
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01253070
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
Bhavana Bhatnagar
NCT02323607
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Therapy-Related Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Therapy-Related Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Therapy-Related Acute Myeloid Leukemia page
11 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Therapy-Related Acute Myeloid Leukemia trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- M.D. Anderson Cancer Center sponsors the most Therapy-Related Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Therapy-Related Acute Myeloid Leukemia condition card totals 11 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.